Focal Segmental Glomerulosclerosis Treatment Study

Clinical Trial Title

PODO: A phase 2 multicenter, open-label, adaptive, sequential cohort trial of PF-06730512 in adult subjects with focal segmental glomerulosclerosis (FSGS).

National Clinical Trial Number:

03448692

Clinical Trial Protocol Description:

A phase 2, 12-week, adaptive, open label, sequential cohort trial (Site PI: V. Peev) evaluating the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple doses in adult subjects with primary focal segmental glomerulosclerosis (FSGS).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are at least 18 years of age.
  • Have a diagnosis of FSGS with IFTA less 50% on biopsy.
  • Have nephrotic syndrome due to FSGS, proteinuria 1.5 g/g.
  • Have a biopsy proven FSGS.
  • Are not pregnant.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Vasil Peev

Contact Information

Vasil Peev